EPY001, a Novel Monoclonal Antibody Against Pseudomonas aeruginosa Targeting OprF
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110380 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Guillaume Lacroix und 1 weiteren Autor:innen. Beteiligte Einrichtung: Epynext Therapeutics, 38000 Grenoble, France. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Pseudomonas aeruginosa, Antibodies, Bacterial, Bacterial Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Epynext Therapeutics, Private company, Epynext Therapeutics. Grant: I-Lab 2021 Bpifrance.
Abstract (Originalsprache)
Pseudomonas aeruginosa (P. aeruginosa) is a high-priority opportunistic pathogen responsible for severe healthcare-associated infections exhibiting multidrug resistance, emphasizing the urgent need for alternative therapeutic strategies. Monoclonal antibodies (mAbs) targeting the highly conserved outer membrane protein OprF represent a promising approach to mitigate its infectivity. OprF, the major and highly conserved outer membrane protein of P. aeruginosa, plays key roles in the pathogenesis of this bacterium, including biofilm formation, host cell adhesion, immune sensing, and resistance to macrophage clearance, making it a crucial factor in virulence and a promising immunotherapeutic target. Here, we report the preclinical evaluation of EPY001, an anti-OprF mAb generated by immunization of a macaque with OprF-containing proteoliposomes. EPY001 exhibited strong nanomolar binding to OprF. Epitope mapping suggests recognition of a conformational epitope, underscoring the value of proteoliposome-based immunization for membrane protein targets. Functional assays provide insights into OprF’s role in biofilm formation, pyocyanin production, and antibiotic resistance. However, in vivo studies revealed that targeting OprF alone is insufficient to protect mice from lethal infection. These findings contribute to ongoing efforts to develop effective alternatives to conventional antibiotics against this resilient pathogen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Epynext Therapeutics, 38000 Grenoble, France.
- Institut de Biologie Structurale (IBS), Université Grenoble Alpes (UGA), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Centre National de la Recherche Scientifique (CNRS), 38000 Grenoble, France.
- CNRS, UMR5525, VetAgro Sup, Grenoble INP, TIMC, University Grenoble Alpes, 38000 Grenoble, France.
ORCID-Profile: Guillaume Lacroix
Förderung
- Epynext Therapeutics, Private company
- Epynext Therapeutics. Grant: I-Lab 2021 Bpifrance
Zitieren
APA
Lacroix, G., & Lenormand, J. L. (2025). EPY001, a Novel Monoclonal Antibody Against Pseudomonas aeruginosa Targeting OprF. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110380
Vancouver
Lacroix G, Lenormand JL. EPY001, a Novel Monoclonal Antibody Against Pseudomonas aeruginosa Targeting OprF. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110380
BibTeX
@article{Lacroix2025,
author = {Lacroix, Guillaume and Lenormand, Jean-Luc},
title = {EPY001, a Novel Monoclonal Antibody Against Pseudomonas aeruginosa Targeting OprF},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110380}
}
EUVIMED